332 related articles for article (PubMed ID: 11308991)
21. Elevated vascular endothelial growth factor levels in sera of patients with lung cancer.
Takigawa N; Segawa Y; Fujimoto N; Hotta K; Eguchi K
Anticancer Res; 1998; 18(2B):1251-4. PubMed ID: 9615796
[TBL] [Abstract][Full Text] [Related]
22. [Assay of matrix metalloproteinase levels and their endogenous inhibitors in patients with laryngeal carcinoma].
Klisho EV; Savenkova OV; Kondakova IV; Perel'muter VM; Choĭnzonov EL; Shishkin DA
Vopr Onkol; 2007; 53(1):26-31. PubMed ID: 17649730
[TBL] [Abstract][Full Text] [Related]
23. Plasma MMP-2 and MMP-9 and their inhibitors TIMP-1 and TIMP-2 during human orthotopic liver transplantation. The effect of aprotinin and the relation to ischemia/reperfusion injury.
Kuyvenhoven JP; Molenaar IQ; Verspaget HW; Veldman MG; Palareti G; Legnani C; Moolenburgh SE; Terpstra OT; Lamers CB; van Hoek B; Porte RJ
Thromb Haemost; 2004 Mar; 91(3):506-13. PubMed ID: 14983226
[TBL] [Abstract][Full Text] [Related]
24. Serum tissue inhibitor of metalloproteinase-2 (TIMP-2) and matrix metalloproteinase-2 in complex with the inhibitor (MMP-2:TIMP-2) as prognostic markers in bladder cancer.
Vasala K; Turpeenniemi-Hujanen T
Clin Biochem; 2007 Jun; 40(9-10):640-4. PubMed ID: 17374529
[TBL] [Abstract][Full Text] [Related]
25. [Zymography--method for quantitation of activity on gelatinase A (pro-MMP-2, 72 kDa) and gelatinase B (pro-MMP-9, 92 kDa) in serum of patients with breast cancer].
Sliwowska I; Kopczyński Z
Wiad Lek; 2007; 60(5-6):241-7. PubMed ID: 17966888
[TBL] [Abstract][Full Text] [Related]
26. Increased serum levels of vascular endothelial growth factor in human crescentic glomerulonephritis.
Nitta K; Uchida K; Kimata N; Honda K; Horita S; Hayashi T; Ishizuka T; Kobayashi H; Kawashima A; Yumura W; Nihei H
Clin Nephrol; 1999 Aug; 52(2):76-82. PubMed ID: 10480217
[TBL] [Abstract][Full Text] [Related]
27. Concentration of vascular endothelial growth factor (VEGF) in the serum of patients with malignant bone tumors.
Holzer G; Obermair A; Koschat M; Preyer O; Kotz R; Trieb K
Med Pediatr Oncol; 2001 Jun; 36(6):601-4. PubMed ID: 11344490
[TBL] [Abstract][Full Text] [Related]
28. [Study on serum vascular endothelial growth factor level in ovarian malignant tumors].
Li L; Wang LM; Zhang W; Zhang JQ; Song HL; Yao DS; Tang Y; Chen XQ; Yang ZH
Zhonghua Fu Chan Ke Za Zhi; 2003 Feb; 38(2):72-6. PubMed ID: 12783691
[TBL] [Abstract][Full Text] [Related]
29. Prognostic value of plasma vascular endothelial growth factor in patients with colorectal cancer.
Nakayama Y; Sako T; Shibao K; Okazaki K; Rempo N; Onitsuka K; Minagawa N; Akahane K; Nagashima N; Nagata N; Itoh H
Anticancer Res; 2002; 22(4):2437-42. PubMed ID: 12174940
[TBL] [Abstract][Full Text] [Related]
30. The surgical treatment of adrenal gland tumors--incidentaloma.
Kolomecki K; Pomorski L; Kuzdak K; Narebski J; Wichman R
Neoplasma; 1999; 46(2):124-7. PubMed ID: 10466437
[TBL] [Abstract][Full Text] [Related]
31. Immunohistochemical expression of vascular endothelial growth factor, matrix metalloproteinase 2, and matrix metalloproteinase 9 in cutaneous melanocytic lesions.
Simonetti O; Lucarini G; Brancorsini D; Nita P; Bernardini ML; Biagini G; Offidani A
Cancer; 2002 Nov; 95(9):1963-70. PubMed ID: 12404291
[TBL] [Abstract][Full Text] [Related]
32. Serum levels of angiogenic cytokines in systemic lupus erythematosus and their correlation with disease activity.
Robak E; Woźniacka A; Sysa-Jedrzejowska A; Stepień H; Robak T
Eur Cytokine Netw; 2001; 12(3):445-52. PubMed ID: 11566625
[TBL] [Abstract][Full Text] [Related]
33. Effect of repeated infliximab therapy on serum matrix metalloproteinases and tissue inhibitors of metalloproteinases in patients with rheumatoid arthritis.
Klimiuk PA; Sierakowski S; Domyslawska I; Chwiecko J
J Rheumatol; 2004 Feb; 31(2):238-42. PubMed ID: 14760791
[TBL] [Abstract][Full Text] [Related]
34. Plasma vascular endothelial growth factor is useful in assessing progression of breast cancer post surgery and during adjuvant treatment.
Wu Y; Saldana L; Chillar R; Vadgama JV
Int J Oncol; 2002 Mar; 20(3):509-16. PubMed ID: 11836562
[TBL] [Abstract][Full Text] [Related]
35. Vascular endothelial growth factor in angiosarcoma.
Fujimoto M; Kiyosawa T; Murata S; Matsuo K; Suzuki H; Sone H; Okuda Y; Nakayama Y; Yaoita H
Anticancer Res; 1998; 18(5B):3725-9. PubMed ID: 9854484
[TBL] [Abstract][Full Text] [Related]
36. Circulating levels of vascular endothelial growth factor in patients with oral squamous cell carcinoma.
Shang ZJ; Li JR; Li ZB
Int J Oral Maxillofac Surg; 2002 Oct; 31(5):495-8. PubMed ID: 12418564
[TBL] [Abstract][Full Text] [Related]
37. Quantitative correlation of serum levels and tumor expression of vascular endothelial growth factor in patients with hepatocellular carcinoma.
Poon RT; Lau CP; Cheung ST; Yu WC; Fan ST
Cancer Res; 2003 Jun; 63(12):3121-6. PubMed ID: 12810638
[TBL] [Abstract][Full Text] [Related]
38. Gelatinase A (MM-2), gelatinase B (MMP-9) and their inhibitors (TIMP 1, TIMP-2) in serum of women with endometriosis: Significant correlation between MMP-2, MMP-9 and their inhibitors without difference in levels of matrix metalloproteinases and tissue inhibitors of metalloproteinases in relation to the severity of endometriosis.
Salata IM; Stojanovic N; Cajdler-Łuba A; Lewandowski KC; Lewiński A
Gynecol Endocrinol; 2008 Jun; 24(6):326-30. PubMed ID: 18584412
[TBL] [Abstract][Full Text] [Related]
39. [Expression of matrix metalloproteinases-9,2,7,and tissue inhibitor of metalloproteinases-1,2,3 mRNA in ovarian tumors and their clinical significance].
Hu XX; Li L; Li DR; Zhang W; Cheng XQ; Zhang JQ; Tang BJ
Ai Zheng; 2004 Oct; 23(10):1194-8. PubMed ID: 15473934
[TBL] [Abstract][Full Text] [Related]
40. Diagnostic value of serum VEGF in women with ovarian tumors.
Oehler MK; Caffier H
Anticancer Res; 1999; 19(4A):2519-22. PubMed ID: 10470186
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
